NEWS

On September 12, 2025, the U.S. Food and Drug Administration (FDA) announced the launch of the FDA Adverse Event Reporting System (FAERS) Public Dashboard for Cosmetic Products, an interactive tool designed to facilitate the public’s ability to query real-time adverse event data on cosmetic products. The user-friendly platform allows users to download report listings or data sets, with reports being updated daily to include the most recent submissions.

On September 17, 2025, China’s National Medical Products Administration (NMPA) announced that, based on the summary of the initial pilot phase, it has decided to launch the second phase of the pilot program for personalized cosmetic services in 15 regions. Starting from October 1, 2025, cosmetic registrants or domestic responsible persons authorized by overseas registrants participating in the pilot program may, at their established specialty stores, directly operated stores, or other business premises, independently carry out small-scale, simple blending and repackaging services of two or more registered general cosmetics on-site, based on consumers’ personalized needs. The pilot period will last for two years.

On September 2, 2025, the Ministry of Food and Drug Safety (MFDS) of South Korea issued Announcement No. 2025-63 to revise the Cosmetic Safety Standards. This announcement will come into effect six months after its publication. However, the revised provisions concerning Cyclopentasiloxane in Annex 2 will take effect three years after the date of publication.

On July 31, 2025, China's National Institutes for Food and Drug Control (NIFDC) released six Technical Guidelines, including the Technical Guidelines for the Study of Hair Dye Cosmetics (Trial) (Draft for Comments), to solicit public opinions. The following is a detailed interpretation of the Technical Guidelines for the Study of Hair Dye Cosmetics (Trial) (Draft for Comments) and the Technical Guidelines for the Study of Quality Control Standards for Hair Dye Cosmetics (Trial). This aims to assist enterprises in keeping up with regulatory and policy changes in a timely manner, ensuring smooth adaptation to regulatory developments.

Recently, the Indonesia Food and Drug Authority (BPOM) has canceled the distribution permits for 21 cosmetic products. The decision was made due to discrepancies between the actual ingredients and the information declared on the product labels, indicating non-compliance with labeling regulations.

This article compiles and summarizes the latest developments in cosmetics regulations in China and globally as of August 2025, covering industry news, newly issued regulations, relevant policy adjustments, and regulatory requirements. It aims to assist enterprises in ensuring compliance and keeping up with global cosmetics regulatory trends.

To help stakeholders stay informed of the latest developments and gain insights into market trends, this article provides a systematic review and in-depth analysis of the cosmetic ingredient filings published by China’s National Medical Products Administration (NMPA) in August 2025. The report mainly covers the number of new ingredient filings during the month, basic information about the filing enterprises, the regional distribution of domestic filers, ingredients that have been filed multiple times, and interpretations of selected ingredients. It aims to offer valuable data support and information references for the cosmetics industry.

This regulation restricts the manufacture, sale, and distribution of cosmetic products in the state of Washington that contain intentionally added formaldehyde or formaldehyde releasers. The objective is to reduce consumer exposure to formaldehyde through the use of cosmetic products, due to its known health risks. The regulation will enter into force on September 28, 2025.

In November 2024, the Indonesian Food and Drug Authority (BPOM) introduced new provisions under Regulation No. 18/2024, governing the labeling, promotion, and advertising of all cosmetic products in Indonesia. The regulation came into effect on November 15, 2024. A 12-month transitional period has been granted to holders of cosmetic distribution licenses that were obtained prior to the effective date, requiring full compliance with the new requirements by November 15, 2025. Relevant companies are advised to pay close attention to the transition timeline and ensure product compliance with the new regulation.

This article provides a consolidated overview of the relevant regulatory notices, supplemented by recent developments in regulatory enforcement activities—such as unannounced inspections and sampling inspections—conducted by the National Medical Products Administration (NMPA) and selected provincial and municipal authorities. The aim is to assist enterprises in staying informed of evolving regulatory trends and to reinforce awareness of quality management and compliance requirements.